Movember 2022 at the University Hospital Olomouc in connection with prostate cancer screening in the Czech Republic

Overview

Objective: The work is focused on evaluating the Movember 2022 event at the University Hospital in Olomouc, the aim of which was to offer men interested in prostate-specific antigen (PSA) serum testing. Individuals with abnormal levels were subsequently followed up for diagnosis. The findings were evaluated in relation to the current prostate cancer screening programme in the Czech Republic.

Design: Observational studies.

Material and Methods: The serum of the subjects was examined for total and freePSA by chemiluminescence immunoassay.

Results: A total of 348 men participated in Movember 2022. The results were evaluated according to the age of the probands. For the group of subjects with a PSA level of 2 -⁠ 10 μg/L, the freePSA value was determined, and the percentage of freePSA/PSA was calculated. A total of 4 patients were captured and subsequently diagnosed with malignant neoplasm of the prostate. These cases are presented as case reports. The results are discussed in relation to the pilot screening program of the Ministry of Health of the Czech Republic (MZCR) for early detection of prostate cancer.

Conclusion: The MZCR methodology sets relatively clear algorithms based on clinical experience, studies and data. The evaluation of the benefits of established screening needs to be evaluated in the long term. Individual survival perspective, health status, associated comorbidities, and age should be central to clinical decisions on screening, diagnosis and  reatment of prostate cancer.

Keywords:

prostate cancer – screening – PSA